Essayer OR - Gratuit
IP In Start-Up Ecosystem
Bio Spectrum
|November 2017
In this age of innovation and technology, Intellectual Property (IP) is an essential element for an organization to sustain and flourish over long periods of time. This is particularly applicable for organizations which rely heavily on R&D to develop technology based solutions for existing problems, and the biotech startup community is no different.
Gone are the days when exploitation of IP used to be limited to large organizations with deep pockets. Today, the technology driven economies have made IP integral and almost synonymous to ‘valuation’ of a start-up or MSME. Many acquisitions of start-ups in the recent past where the patented technology was at the core of the deal, have corroborated this philosophy.
As is often the case with start-ups, funding and sustainability become major hurdles that need to be timely overcome for them to stay alive in the game. The challenge is amplified multi-fold for a biotech start-up, where the lab-to-market incubation time is relatively long. This means that for the start-up to continue its quest for success, funding must keep coming in regularly, which in-turn means keeping the investors happy.
While the funding agencies in the recent times have widened their arms to the start-up community, the ROI expectations are also higher than ever before. Investors are on a constant look out for a sense of security to confirm that every dollar is well spent, and that the organization believes in its technology, is looking at safeguarding its interests and has the intent to be aggressive against competition emulating them. IP protection provides that comfort.
Though broadly IP encompasses trademarks, copyrights, industrial design rights, and trade secrets, patents form the most significant chunk for tech-driven industries. Simply put, patents provide an innovator a monopoly over a technological invention in a country, typically for 20 years, and act as exclusionary rights that prevent a third party from making, using, selling or importing the patented innovation in a geography. The idea is to incentivize innovation and advancement of technology by recognizing and rewarding those who innovate.
Cette histoire est tirée de l'édition November 2017 de Bio Spectrum.
Abonnez-vous à Magzter GOLD pour accéder à des milliers d'histoires premium sélectionnées et à plus de 9 000 magazines et journaux.
Déjà abonné ? Se connecter
PLUS D'HISTOIRES DE Bio Spectrum
Bio Spectrum
Can India's CDMOS Lead the Next Biopharma Wave?
India's Contract, Development, and Manufacturing Organisation (CDMO) sector is projected to grow from $3-3.5 billion today to $22-25 billion by 2035, noted Boston Consulting Group (BCG).
8 mins
March 2026
Bio Spectrum
Telangana turns catalyst for innovation
Telangana is at a pivotal moment in its journey as a global life sciences hub.
6 mins
March 2026
Bio Spectrum
Is AI the New Weapon in the Fight to End TB?
A report released at the India AI Impact Summit 2026, organised by the Government of India, reveals that artificial intelligence (AI) is being successfully deployed at scale across India’s public healthcare system to address the growing burden of tuberculosis (TB).
2 mins
March 2026
Bio Spectrum
ChemWerth on-boards Chandrakanth Reddy as new GSM to increase generic API footprint in India
US-based ChemWerth, Inc., a global leader in generic active pharmaceutical ingredient (API) development and supply, continues to expand its footprint and strengthen its position in the Indian market.
1 min
March 2026
Bio Spectrum
Beyond the Glass Ceiling: Women-Led Companies Shaping India's Health Economy
Over the past decade, women entrepreneurs have gained strong ground in India's healthcare sector, building ventures in diagnostics, FemTech, biotech, and care delivery.
5 mins
March 2026
Bio Spectrum
"There needs to be a collaborative effort between innovators and policymakers to create frameworks that ensure safety without stifling progress"
Started in 2021, Decode Age, one of the pioneers in Longevity Research in India, entered its next phase of growth following its Pre-Series A funding round, led by Granules India.
5 mins
March 2026
Bio Spectrum
Rainbow Children's Medicare appoints Abrarali Dalal as Chief Executive Officer
Rainbow Children's Medicare, a leading provider of paediatrics, perinatal, and women's healthcare services in India, has announced the appointment of Abrarali Dalal as Chief Executive Officer, effective from January 20, 2026.
1 min
March 2026
Bio Spectrum
Haleon ropes in Kedar Lele as President for India Subcontinent
Haleon, a British multinational consumer healthcare company has announced the appointment of Kedar Lele as President for India Subcontinent (ISC), effective January 2026.
1 min
March 2026
Bio Spectrum
Centre revises Startup Recognition Framework to strengthen Startup India Action Plan
The government of India has revamped the Startup Recognition Framework to further strengthen the Startup India Action Plan and take forward the Prime Minister's vision of positioning India as a global innovation powerhouse, manufacturing-led economy and hub for emerging tech.
1 min
March 2026
Bio Spectrum
"In the coming 5 years from now, no Indian CROS will grow or survive without the use of AI"
In January 2026, Ahmedabad-based Veeda Lifesciences announced a strategic leadership transition that marks a new chapter in the company's evolution.
5 mins
March 2026
Translate
Change font size

